Authors
John Burn, D Timothy Bishop, Jukka-Pekka Mecklin, Finlay Macrae, Gabriela Möslein, Sylviane Olschwang, Marie-Luise Bisgaard, Raj Ramesar, Diana Eccles, Eamonn R Maher, Lucio Bertario, Heikki J Jarvinen, Annika Lindblom, D Gareth Evans, Jan Lubinski, Patrick J Morrison, Judy WC Ho, Hans FA Vasen, Lucy Side, Huw JW Thomas, Rodney J Scott, Malcolm Dunlop, Gail Barker, Faye Elliott, Jeremy R Jass, Ricardo Fodde, Henry T Lynch, John C Mathers
Publication date
2008/12/11
Journal
New England Journal of Medicine
Volume
359
Issue
24
Pages
2567-2578
Publisher
Massachusetts Medical Society
Description
Background
Observational and epidemiologic data indicate that the use of aspirin reduces the risk of colorectal neoplasia; however, the effects of aspirin in the Lynch syndrome (hereditary nonpolyposis colon cancer) are not known. Resistant starch has been associated with an antineoplastic effect on the colon.
Methods
In a randomized, placebo-controlled trial, we used a two-by-two design to investigate the effects of aspirin, at a dose of 600 mg per day, and resistant starch (Novelose), at a dose of 30 g per day, in reducing the risk of adenoma and carcinoma among persons with the Lynch syndrome.
Results
Among 1071 persons in 43 centers, 62 were ineligible to participate in the study, 72 did not enter the study, and 191 withdrew from the study. These three categories were equally distributed across the study groups. Over a mean period of 29 months (range, 7 to 74), colonic adenoma or carcinoma developed …
Total citations
Scholar articles
J Burn, DT Bishop, JP Mecklin, F Macrae, G Möslein… - New England Journal of Medicine, 2008